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Housing male or female rats on ground corn-
cob bedding disrupts sexual behavior and
ovarian cyclicity. This observation led to the
characterization of an endocrine disruptor in
corn (Markaverich et al. 2002a). The dis-
ruptor activity was identiﬁed as a mixture of
9,12-oxy-10,13-dihydroxyoctadecanoic acid
and 10,13-oxy-9,12-dihydroxyoctadecanoic
acid [tetrahydrofurandiols (THF-diols)]
(Markaverich et al. 2002b). Administration of
an equimolar mixture of the synthetic THF-
diols as a drinking solution disrupted male and
female sexual behavior and ovarian cyclicity in
rats (Mani et al. 2005; Markaverich et al.
2002b). The lowest observed adverse effects
level (LOAEL) of the compounds was
0.5–1.0 ppm (Markaverich et al. 2007).
Although direct effects of the THF-diols on
human reproductive function have not been
described, they appear to be components of
corn food products for human consumption
(Markaverich et al. 2002a). Commercial uses
for ground or milled corncob include grit for
metal ﬁnishing and blast cleaning, absorbents
for aqueous spills, pesticide carriers for ﬁre ant
and grub control, feeds and feed additives and
animal health products. Thus, human and ani-
mal exposures to the THF-diols are likely
(Markaverich et al. 2002a). The actual level of
THF-diols in corn products has not been
quantiﬁed, and therefore their potential toxi-
cology in humans is unknown. Nevertheless,
the THF-diols clearly disrupt reproductive
function in rats and likely have a significant
effect on biomedical research.
In addition to their endocrine disruptive
properties, the THF-diols were purified and
identified on the basis of their abilities to
stimulate the proliferation of estrogen receptor
(ER) positive (MCF-7) and ER-negative
(MDA-MD-231) human breast cancer cells
in vitro and to promote the growth of PC-3
human prostate cancer cell xenografts in
athymic nude mice (Markaverich et al. 2002a).
Thus, the mitogenic properties of the com-
pounds may also influence the growth of a
variety of cancers. The THF-diols are likely
derived from linoleic acid metabolism and are
chemically related to prostaglandins, hydroxy-
eicosatetraenoic acids (HETEs), and hydroxy-
octadecenoic acids (HODEs). It is well known
that EGF stimulation of cell proliferation
involves membrane-associated phospho-
lipase A2 (PLA2)–mediated release of arachi-
donic acid and linoleic acids from the cell
membrane. The conversion of these fatty acids
to prostaglandins (Nolan et al. 1988), arachi-
donic and/or linoleic acid metabolites
(9-hydroxyoctadecadienoic acid, 9-HODE;
12-hydroxyoctadecadienoic acid, 12-HODE
and 13-hydroxyoctadecadienoic acid (13-
HODE) mediates epidermal growth factor
(EGF)-stimulation of [3H]thymidine incorpo-
ration into DNA (Glasgow and Eling 1990,
1994), cell cycle transition, and apoptosis
(Durgam and Fernandes 1997; Kachhap et al.
2000; Tong et al. 2002). Many of these path-
ways were defined by assessing the effects of
inhibitors of PLA2 (quinacrine), LOX (nordi-
hydroguaiaretic acid, NDGA; REV-5901) and
COX (indomethacin, NDGA) on cell prolifer-
ation (Glasgow and Eling 1990, 1994;
Natarajan et al. 1997; Reddy et al. 1997).
Thus, the close structural relationship of the
THF-diols to the HETEs and HODEs may
provide a key to the mechanism of action of
the THF-diols in terms of their mitogenic
properties. The present studies assessed
these possibilities.
Materials and Methods
Chemical and reagents. Linoleic acid,
indomethacin, baicalein, REV-5091, and nordi-
hydroguaiaretic acid (NDGA) were purchased
from Cayman Chemical (Ann Arbor, MI).
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BACKGROUND: We characterized an endocrine disruptor from ground corncob bedding material
that interferes with male and female sexual behavior and ovarian cyclicity in rats and stimulates
estrogen receptor (ER)-positive and ER-negative breast cancer cell proliferation. The agents were
identiﬁed as an isomeric mixture of tetrahydrofurandiols (THF-diols; 9,12-oxy-10,13-dihydroxy-
octadecanoic acid and 10,13-oxy-9,12-dihydroxyoctadecanoic acid). Synthetic THF-diols inhib-
ited rat male and female sexual behavior at oral concentrations of 0.5–1 ppm, and stimulated
MCF-7 human breast cancer cell proliferation in vitro.
OBJECTIVES: Because THF-diols are derived from lipoxygenase and cyclooxygenase pathways, we
suspected that these compounds may regulate cell proliferation by modulating speciﬁc enzymatic
sites involved in linoleic acid metabolism including phospholipase A2 (PLA2), lipoxygenases
(LOX-5 and LOX-12), cyclooxygenases (COX-1 and COX-2), and closely coupled enzymes
including aromatase (AROM).
METHODS: MCF-7 human breast cancer cells were treated with inhibitors for PLA2 (quinacrine),
lipoxygenases (LOX-5 and LOX-12; baicalein, REV-5091, nordihydroguaiaretic acid), cyclooxyge-
nases (COX-1, COX-2, indomethacin), and AROM (formestane). The effects of these enzyme
inhibitors on cell proliferation in response to THF-diols or estradiol (E2) were assessed. THF-diol
modulation of the expression (RNA and protein) of these enzymes was also evaluated by quantita-
tive real-time PCR (QPCR) and Western blot analyses.
RESULTS: The enzyme inhibition and gene expression (RNA and protein) studies identiﬁed PLA2,
LOX-5, LOX-12, COX-2, and perhaps AROM as likely sites of THF-diol regulation in MCF-7
cells. COX-1 was not affected by THF-diol treatment.
DISCUSSION: THF-diol stimulation of MCF-7 cell proliferation is mediated through effects on the
expression of the PLA2, COX-2, LOX-5, and LOX-12 genes and/or their respective enzyme activi-
ties. The products of these enzymes, including prostaglandins, hydroxyeicosatetraenoic acids
(HETEs) and hydroxyoctadecenoic acids (HODEs), are well-established mitogens in normal and
malignant cells. Therefore, it is likely that these compounds are involved in the mechanism of
action of THF-diols in breast cancer cells. Although the formestane inhibition studies suggested
that AROM activity might be modulated by THF-diols, this was not confirmed by the gene
expression studies.
KEY WORDS: breast cancer cells, COX-2, LOX-5, LOX-12, and PLA2 gene expression, THF-diols.
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(E2) were from Sigma Chemical Co. (St.
Louis, MO). Compounds were dissolved in
100% ethanol (EtOH)for addition to the
tissue culture medium. Primers for quantita-
tive real-time real-time polymerase chain reac-
tion (QPCR) studies were purchased from
QIAGEN (Valencia, CA). GIBCO general tis-
sue culture supplies and calf serum or fetal calf
serum were from Invitrogen (Carlsbad, CA).
Equimolar mixtures of THF-diol isomers were
synthesized and validated as described
(Markaverich et al. 2002b, 2005).
Assessment of PLA2, COX, LOX, and
AROM inhibitors on MCF-7 cell proliferation.
Stock cultures of MCF-7 human breast cancer
cells were carried in T-75 or T-150 flasks in
Dulbecco’s modiﬁed Eagle’s medium (DMEM)
containing 10% calf serum (Markaverich et al.
1988). Enzyme inhibition studies were per-
formed to identify speciﬁc targets of THF-diol
regulation in MCF-7 cells. Although such
studies are often difficult to interpret, unless
complete inhibition is achieved and non-
speciﬁc toxicity is not a problem, the potential
for these types of problems was reduced by the
completion of detailed dose–response studies
for each of the enzyme inhibitors. In this way,
the lowest effective concentrations of the com-
pounds required to minimally inhibit cell pro-
liferation without signiﬁcant cell toxicity were
determined. These studies were performed in
phenol red containing DMEM supplemented
with 5% fetal calf serum under conditions
where MCF-7 cells elicit normal doubling
times and used well-established dose ranges of
these enzyme inhibitors shown to inhibit these
enzymes in cultured cells in vitro (Glasgow and
Eling 1990, 1994; Natarajan et al. 1997;
Reddy et al. 1997). 
We set our end point at cell proliferation
rather than looking at enzyme activity per se for
a number of reasons. First, our studies were
focused on blocking the stimulatory effect of
THF-diols on cell proliferation with these
enzyme inhibitors, as we were probing the
mechanism of action of THF-diols. Second,
enzyme inhibitor studies are difﬁcult to inter-
pret, particularly when studying the incorpora-
tion of radiolabeled precursors into endogenous
pools. Third, because we were also assessing the
expression (RNA and protein) of each of these
genes by QPCR and Western blot analysis,
enzyme activity assays were not required.
Although the enzyme inhibitors described
here are studied typically in DMEM contain-
ing phenol red supplemented with normal calf
serum, the present studies used phenol red
free–medium containing 5% charcoal-stripped
fetal calf serum. This media substitution was
required so that the mitogenic activity of the
THF-diols in MCF-7 cells could be assessed
under conditions in which a significant
increase in cell number relative to that in
EtOH controls could be observed in response
to the THF-diols (Markaverich et al. 2002a).
This would not have been possible in media
containing an estrogenic substance such as
phenol red (Berthois et al. 1986). Thus, there
was often little or no difference between EtOH
controls and inhibitor-treated cells, as the con-
trols proliferate very slowly and the magnitude
of the inhibitory response is very small.
Nevertheless, the effects of the various
enzyme inhibitors on THF-diol or E2 stimula-
tion of MCF-7 cell proliferation were signiﬁ-
cant. Cell counts on viable, attached cells
isolated from the monolayers were determined
on the basis of trypan blue dye exclusion. For
inhibition studies, MCF-7 cells (20,000
cells/well) were plated in 24-well multiplates
and grown in 1 mL of phenol red–free DMEM
supplemented with 5% charcoal-stripped fetal
calf serum. Forty-eight hours after plating
(day 0), quadruplicate wells for each treatment
group were treated with 2 µL EtOH (controls),
24 µM THF-diol, 4 nM E2, or the indicated
concentration of enzyme inhibitor (alone or in
combination with THF-diol or E2) added to
the medium in a total of 2 µL of EtOH. The
stimulatory doses of THF-diols (24 µM) and
E2 (4 nM) were based on dose–response and
time studies that optimized this assay system
for assessing the response of MCF-7 cells to
these compounds (Markaverich et al. 2002a,
2005). Attached cells were collected 6 days
after treatment by trypsinization and washed in
Hanks balanced salts solution (HBSS;
GIBCO; Invitrogen) by resuspension and cen-
trifugation. We determined viable cell number
from the monolayers by hemocytometer
counts based upon trypan blue dye exclusion
(Zhu et al. 2001). Each experiment was
repeated a minimum of 3 times. Data were
expressed as the mean ± SE, and results from
representative experiments were analyzed by
Instat (Graphpad Software, San Diego, CA) by
analysis of variance (ANOVA) with a Tukey
test on the treatment means or with an
unpaired two-tailed t-test.
THF-diol effects on LOX-5, LOX-12,
COX-1, COX-2, PLA2, and AROM gene
expression in MCF-7 breast cancer cells. For
gene expression studies, MCF-7 cells were
grown to approximately 50% confluency in
100 mm petri dishes containing phenol
red–free DMEM supplemented with 5%
charcoal-stripped fetal calf serum. The cells
were treated with 2 µL EtOH or 24 µM THF-
diol added to the medium in 2 µL of EtOH.
Twenty-four hours after treatment, the mono-
layers of cells from triplicate plates containing
EtOH controls or THF-diol treatment groups
were collected with 0.25% trypsin-EDTA
[4 mL; (Markaverich et al. 1988)] and approxi-
mately 5.0 × 106 cells from each plate were
centrifuged (2,000 × g for 5 min) in RNAse-
and DNAse-free tubes, resuspended in 1 mL of
phosphate-buffered saline (PBS) and 4 mL of
RNAlater (QIAGEN) and stored at –20°C.
The frozen cells were thawed on ice, collected
by centrifugation, and lysed by resuspension in
0.6 mL of RTL buffer (QIAGEN) containing
β-mercaptoethanol. RNA from the cell pellets
was puriﬁed using the QIAGEN RNeasy kit
spin protocol (Markaverich et al. 2006). RNA
integrity was confirmed on an Agilent 2100
Bioanalyzer. The iScript cDNA Synthesis kit
(Bio-Rad, Hercules, CA) was used to prepare
cDNA from RNA isolated from MCF-7 cells
from three replicate experiments for each treat-
ment group. This cDNA was used as template
for QPCR studies.
Prevalidated, PCR primers (QIAGEN)
were used for the quantiﬁcation of THF-diol
effects on COX-1 [PTGS1, prostaglandin–
endoperoxide synthase 1 (prostaglandin G/H
synthase and cyclooxygenase; RefSeq accession
nos. NM_000962, NM_080591, respectively;
http://www.ncbi.nlm.nih.gov/RefSeq/)],
COX-2 [PTGS2, prostaglandin–endoperoxide
synthase 2 (prostaglandin G/H synthase and
cyclooxygenase; RefSeq accession no.
NM_000963)], LOX-5 (Alox5, arachidonate
5-lipoxygenase, RefSeq accession no.
NM_000698), LOX-12 (Alox12, arachidonate
12-lipoxygenase, RefSeq accession no.
NM_000697), PLA2 [PLA2G6; phospholipase
A2, group VI (cytosolic, calcium-independent,
RefSeq accession nos. NM_001004426,
NM_003560)], and aromatase (AROM,
CYP19A1, cytochrome P450, family 19, sub-
family A, polypeptide 1; RefSeq accession no.
NM_031226) gene expression. QPCR was per-
formed in MyiQ SYBR Green Supermix (Bio-
Rad) and quantified on MyiQ Single Color
Real-Time PCR Detection System using MyiQ
Optical System software, version 2.0 (Bio-Rad).
Each primer pair was validated by the genera-
tion of standard serial dilution and melt curves
on cDNA from MCF-7 cells to ensure that
reaction efﬁciencies of 90–110% and correla-
tion coefﬁcients of > 0.995 were obtained. Melt
curves demonstrating a single product with an
appropriate melting temperature confirmed
that primer dimerization did not contribute to
the signal. Products of the optimized reactions
were also analyzed by agarose gel electrophoresis
(Markaverich et al. 2006) to ensure that the size
of the amplicon corresponded to the data pro-
vided by QIAGEN for each primer pair.
Western blot analyses of protein expression
in MCF-7 cells. MCF-7 cells grown and treated
with THF-diols as described above for 8 days
were lysed with QIAGEN RTL buffer on pass
through Qiashredders. Proteins in the extract
were precipitated with 4 vol ice-cold acetone
and collected by centrifugation. The pellets
were dried under nitrogen, re-dissolved in sam-
ple extraction buffer [0.05 M Tris, pH 7.4,
8 M urea, 1% sodium dodecyl sulfate (SDS),
0.1% β-mercaptoethanol] containing 0.02%
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Aldrich, Milwaukee, WI) and diluted 2:1 with
sample loading buffer (0.0625 M Tris, pH 6.8,
20% glycerol  plus bromophenol blue). The
solubilized samples were centrifuged and heated
for 3 min at 90°C. The cooled samples were
resolved on 4–12% NuPAGE Bis–Tris gradi-
ent gels using MES running buffer (Invitrogen,
Carlsbad, CA). The electrophoresed proteins
were transferred to nitrocellulose membrane
(Trans-Blot Transfer medium; Bio-Rad),
washed, and blocked in Tris-buffered saline
(1× TBS) with 5.0% nonfat dried milk. The
rinsed membranes were incubated overnight
with primary antibody (1:100 dilution).
Primary antibodies (LOX-5, LOX-12, AROM,
PLA2, COX-1, COX-2, β-actin) suitable for
Western blot analysis were purchased from
Santa Cruz Biotechnologies (Santa Cruz, CA).
After a 60-min incubation with the appropriate
species–specific horseradish peroxidase–
conjugated secondary antibody (Upstate,
Temucula, CA), speciﬁc antigens were detected
by the Visualizer Western Blot Detection kit
(Upstate, Charlottesville, VA) on X-OMAT
Scientific Imaging film (Eastman Kodak
Company Rochester, NY). For the protein
bands to be normalized with β-actin, the nitro-
cellulose membrane was stripped with
Stripping Buffer II (0.4 M glycine, 0.2% SDS,
Tween-20, pH 2.2) according to the manufac-
turer’s instructions before reprobing. All blots
were quantiﬁed with UNSCAN-IT Gel soft-
ware (Silk Scientiﬁc Software, Orem, UT).
Statistical analyses. Data from the enzyme
inhibitor studies were representative of three
separate experimental replicates that yielded
equivalent results. The data in the Table 1 rep-
resent the mean ± SE for each treatment group
with a minimum of three wells per group. Data
were analyzed statistically by ANOVA and a
Tukey test on the means (Instat) and are repre-
sentative of three replicate experiments. Results
from QPCR (Figure 1) on triplicate pools of
RNA for each treatment group were normal-
ized to 18S RNA (GenBank accession no.
X03205; http://www.ncbi.nlm.nih.gov/
GenBank) and analyzed statistically by Instat
with a two-tailed t-test on the treatment means.
The Western blot analyses (Figure 2) were
repeated a minimum of 3 times and the data in
Figure 2 represent three repetitive experiments.
The gel scans (Figure 2B) were normalized to
the EtOH control.
Results
Effects of enzyme inhibitors on the response of
MCF-7 cells to THF-diol or E2. The results of
the enzyme inhibitor studies are shown in
Table 1. Initially, we assessed the effects of the
PLA2 inhibitor quinacrine on MCF-7 cell pro-
liferation. PLA2 releases arachidonic and line-
oleic acids from the cell membrane, generating
key components in the lipogenic pathways
including prostaglandins, HETEs, and HODEs
that control cell proliferation. 2.5 µM quina-
crine signiﬁcantly inhibited (p < 0.05) the pro-
liferation of MCF-7 cells relative to controls.
Quinacrine also reduced the stimulatory
response of the THF-diols (p < 0.001) and E2
(p < 0.001), suggesting that PLA2 is an enzy-
matic site of THF-diol regulation. Linoleic
acid stimulated MCF-7 cell proliferation (p <
0.001) and quinacrine was unable to block this
response (compare linoleic acid group with
linoleic acid plus quinacrine group), further
suggesting THF-diols regulate MCF-7 prolif-
eration by modulating PLA2.
Indomethacin failed to affect MCF-7 cell
proliferation relative to that of EtOH controls
(Table 1) and this inhibitor did not block
THF-diol or E2 stimulation of MCF-7 cell pro-
liferation. These data suggested that the COX
enzymes might not be regulated by THF-
diols. Ten micromolars REV-5901 (LOX-5
inhibitor) alone failed to significantly affect
MCF-7 proliferation. However, this LOX-5
inhibitor blocked the response of the cells to
THF-diols or E2 (Table 1 compares THF-diol
with THF-diol plus REV-5901 and E2 with E2
plus REV-5091 treatment groups) even though
the magnitude of the stimulatory response to
the THF-diols relative to EtOH controls
(p < 0.001) was nearly equivalent to that
obtained with E2. That REV-5091 partially
blocked (p < 0.001) the response of MCF-7
cells to THF-diols suggests that LOX-5 could
be an enzymatic site of THF-diol regulation.
Similar response proﬁles were obtained with the
speciﬁc LOX-12 inhibitor baicalein (Table 1),
which also suggests that LOX-12 is a site of
action of THF-diols and estradiol in MCF-7
cells. Thus, it was not surprising that the stimu-
latory response to THF-diols (p < 0.001) or E2
(p < 0.001) was blocked by the nonspecific
LOX inhibitor NDGA (compare THF with
THF + NDGA; E2 with E2 + NDGA), further
suggesting LOX enzymes are involved in
mitogenic response to THF-diols and E2.
Formestane (50 nM) failed to affect the
growth of MCF-7 cells grown in phenol
red–free DMEM. However the AROM
inhibitor signiﬁcantly (p < 0.01) reduced the
proliferative response of MCF-7 cells to the
THF-diols by about 30% (compare THF-diol
with THF-diol plus formestane treatment
groups; Table 1). Thus, it is possible that the
THF-diols may stimulate estrogen biosynthesis
in MCF-7 cells by affecting AROM, although
this requires further conﬁrmation.
Effects of THF-diols on gene expression in
the arachidonic acid and linoleic acid path-
ways in MCF-7 cells. The enzyme inhibitor
studies tentatively identified PLA2, COX,
LOX-5, LOX-12, and possibly AROM as sites
of THF-diol regulation. To further explore
these possibilities, we prepared RNA from
MCF-7 cells 24 hr after treatment with EtOH
(controls) or the THF-diols and quantified
treatment effects on the expression of PLA2,
LOX-5, LOX-12, COX-1, COX-2, and AROM
genes by QPCR (Figure 1). THF-diol treat-
ment significantly (p < 0.001) increased the
expression of PLA2, LOX-5, LOX-12, and
COX-2 genes, conﬁrming results obtained with
the enzymatic inhibitors (Table 1). Signiﬁcant
effects on AROM were not observed. Together
the results suggest that THF-diols may be
THF-diols and PLA2, LOX, and COX gene expression
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Figure 1. QPCR analysis of PLA2, COX-1, COX-2,
LOX-5, LOX-12, and AROM gene expression in
MCF-7 breast cancer cells. MCF-7 cells were
treated for 24 hr with 2 µL EtOH (controls) or 24 µM
THF-diols in 2 µL EtOH vehicle. RNA was prepared
and analyzed by QPCR. The results represent the
mean ± SE for three independent RNA sets normal-
ized to 18S RNA. Data were analyzed by ANOVA and
a two-tailed t-test on the treatment means (Instat).
*p < 0.001.
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Figure 2. Western blot of expressed proteins in
MCF-7 Cells. MCF-7 cells were treated with 24 µM
THF-diol as described in Figure 1. Eight days after
treatment, the cells were harvested and the protein
extracts were subjected to SDS–polyacrylamide
gel electrophoresis and probed by Western blot
analysis with antibodies to PLA2, COX-1, COX-2,
LOX-5, LOX-12, and AROM. (A) Immunostained pro-
teins. (B) Graphic representation of the data in A
after quantification of the bands with Un-Scan-it-
Gel (Silk Scientiﬁc Software, Orem, Utah).
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Bmodulating AROM activity and/or substrate
and cofactor availability, and so forth, but
probably do not affect the expression of this
protein. The QPCR studies also revealed that
COX-1 gene expression was not significantly
affected by THF-diols at this time (24 hr).
Although COX-2 gene expression was affected
by THF-diol treatment, the negligible effects
on COX-1 may be partly responsible for the
inability of indomethacin to block THF-diol
stimulation of MCF-7 cell proliferation.
THF-diol effects on the protein expression
patterns of PLA2, LOX-5, LOX-12, COX-1,
and COX-2 proteins on day 8 after treatment
(Figure 2) mirrored the RNA expression data
(Figure 1). THF-diols increased the levels of
expression of LOX-5, LOX-12, PLA2, and
COX-2 but not AROM. The data in Figure 2
represent three separate Western blots, all
yielding essentially identical results, and there-
fore, are highly significant. Together the
inhibitor studies, QPCR studies, and Western
blots strongly suggest LOX-5, LOX-12, PLA2,
and COX-1 genes and their respective proteins
are sites of THF-diol regulation.
Discussion
The studies described in this article were con-
ducted to determine whether speciﬁc enzymes
involved in arachidonic and linoleic acid
metabolism are sites of THF-diol regulation in
MCF- human breast cancer cells. We sus-
pected that PLA2, LOX-5, LOX-12, COX-1,
and COX-2 could be likely candidates for
THF-diol regulation, as the products of these
enzymes, including prostaglandins (Joubert
et al. 2003), HODEs, and HETEs (Kim et al.
2005; Nie et al. 2006), are well-known regula-
tors of cell growth. Aromatase was also investi-
gated because of the involvement of this
enzyme in estrogen biosynthesis in malignant
tissues (Brodie et al. 1999, 2001) and its close
association with COX products that regulate
MCF-7 cells (Brueggemeier et al. 2001).
Because THF-diols are likely derived from
linoleic acid, a PLA2 product (Table 1), we
assessed the effects of quinacrine (a PLA2
inhibitor) on THF-diol stimulation of MCF-7
cell proliferation. Quinacrine completely
blocked THF-diol stimulation of MCF-7 cell
proliferation (Table 1) and exogenous linoleic
acid stimulated MCF-7 cells in the absence or
presence of quinacrine (Table 1). These ﬁnd-
ings conﬁrmed that the inhibition of cell pro-
liferation by quinacrine speciﬁcally involved a
block in linoleic acid production and suggested
that THF-diols were regulating cell prolifera-
tion at the level of PLA2. As expected, E2 over-
came quinacrine inhibition of MCF-7 cell
proliferation (Table 1). This ﬁnding is consis-
tent with the well-known effects of E2 on
PLA2 gene expression in breast cancer cells
(Thomas et al. 2006). E2 was included in these
studies as an additional control to demonstrate
reversibility of the various inhibitors and rule
out drug toxicity.
It is interesting to note that THF-diols
and E2 modulate PLA2 in MCF-7 cells, as
THF-diols also stimulate ER-negative MDA-
MD-231 breast cancer cells. The mitogenic
response to these compounds obviously does
not require ER and is not blocked by antiestro-
gens (Markaverich et al. 2002a). Consequently,
the THF-diols and E2 likely regulate PLA2 via
different mechanisms. That THF-diols stimu-
late PLA2 is not surprising, as inhibition of this
enzyme is directly correlated with the inhibition
of breast (MCF-7, MDA-MD-231 cells) and
prostate cancer (PC-3, PC-3M, DU-1245 cells)
cell proliferation in vitro or in vivo when grown
as xenografts in nude mice (de Souza et al.
1997; Jaattela et al. 1995). PLA2 concentration
is closely related to the malignant potential.
Breast cancer specimens contain higher concen-
trations of PLA2 than benign breast tissues, and
low PLA2 activity is associated with longer dis-
ease-free intervals and survival even though no
relationship was noted between PLA and ER or
progesterone receptor status (Yamashita et al.
1993, 1994, 1995). These ﬁndings are consis-
tent with our results suggesting that PLA2 is
involved in MCF-7 cell proliferation. Mitogens
such as the THF-diols likely regulate prolifera-
tion by stimulating this enzyme.
Studies with the other enzyme inhibitors
delineated other possible sites of THF-diol
action. Although Indomethacin (a COX-1 and
COX-2 inhibitor) failed to antagonize THF-
diol stimulation of MCF-7 cells, REV-5901
(LOX-5), Baicalein (LOX-12), and NDGA
(nonspeciﬁc LOX inhibitor) blocked the mito-
genic response to THF-diols (Table 1). This is
not surprising in view of the fact that in
MCF-7, MCF-10, and MDA-MD-231 breast
cancer cells, LOX, but not COX inhibitors,
blocked EGF/transforming growth factor-α
stimulation of 12-HODE and 13-HODE pro-
duction and cellular proliferation (Natarajan
Markaverich et al.
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Table 1. Effects of enzyme inhibitors on THF-diol or E2 stimulation of MCF-7 cell proliferation at 24 hr.
Cells/well × 10–4
Enzyme/inhibitor Treatment (± SE)
Phospholipase A2 EtOH 7.63  ± 0.89
Quinacrine (Quin) Quinacrine (2.5 µM) 2.00 ± 0.27a
THF-diol (24 µM) 35.75 ± 2.15b
E2 (5 nM) 43.75 ± 1.41b
THF + Quin 6.50 ± 0.46
E2 + Quin 10.38 ± 0.92
Phospholipase A2 EtOH 9.63 ± 0.65
Quinacrine (Quin) Quinacrine (2.5 µM) 1.63 ± 0.38c
Linoleic acid (36 µM) 13.13 ± 0.92
Quin + linoleic acid 11.63 ± 0.625
COX-1 and COX-2 EtOH 7.38 ± 0.75
Indomethacin (Indo) Indomethacin (50 µM) 6.25 ± 0.65
THF-Diol (24 µM) 57.75 ± 1.89d
E2 5 (nM) 76.38 ± 2.9d
Indo +THF-diol 62.00 ± 2.73d
Indo + E2 71.12 ± 2.89d
LOX-5 EtOH 6.25 ± 0.45
REV-5901 (Rev) REV-5901 (10 µM) 6.25 ± 0.49
THF-Diol (24 µM) 68.75 ± 2.67e
E2 (5 nM) 83.13 ± 5.19e
REV + THF-Diol 41.25 ± 1.7e,f
REV + E2 62.88 ± 4.02e,f
LOX-12 EtOH 6.5 ± 0.53
Baicalein (Baic) Baicalein (5 µM) 5.63 ± 0.53
THF-Diol (24 µM) 59.00 ± 2.82g
5 nM E2 63.38 ± 1.95g
Baic + THF-diol 47.2 ± 1.7g,h
Baic + E2 55.88 ± 1.69g,i
LOX-5 and LOX-12 EtOH 6.875 ± 0.79
NDGA NDGA (25 µM) 8.25 ± 0.96
THF-diol (24 µM) 49.25 ± 1.37j
E2 (5 nM) 59.625 ± 4.24j
THF + NDGA 10.375 ± 0.63
E2 + NDGA 15.0 ± 0.89
Aromatase EtOH 7.25 ± 0.90
Formestane (Form) Formestane (50 nM) 8.5 ± 1.05
THF-diol 24 µM) 65.25 ± 3.94k
E2 (5 nM) 68.88 ± 3.94k
Form + THF-diol 53.12 ± 3.19k
Form + E2 64.75 ± 1.95k
aSignificant difference from EtOH group (p < 0.05). bSignificant difference from all other groups (p < 0.001). cSignificant
difference from all other groups (p < 0.01). dSignificant difference from EtOH and indomethacin groups (p < 0.001).
eSignificant difference from EtOH or REV-5901 groups (p < 0.001). fSignificant difference from E2 or THF-Diol groups
(p < 0.001). gSignificant difference from EtOH group (p < 0.001). hSignificant difference from THF-Diol group (p < 0.001).
iSignificant difference from E2 group (p < 0.05). jSignificant difference from EtOH, NDGA, THF + NDGA and E2 + NDGA
groups (p < 0.001). kSigniﬁcant difference from EtOH and formestane groups (p < 0.001).et al. 1997; Reddy et al. 1997). LOX products
(5-HETE, 12-HETE) reversed these effects
(Natarajan et al. 1997). EGF stimulation
of MCF-7 cell proliferation causes a dose-
dependent increase in the formation of LOX
products, including 12-HETE (Tong et al.
2002). Thus, lipoxygenase products (HODEs,
HETEs) stimulate proliferation of these cells.
We also investigated THF-diol effects on
AROM because of the well-known association
between COX activity and PGE2 induction of
this enzyme in MCF-7 breast cancer cells. COX
products generate estrogens required for MCF-7
cell proliferation (Brueggemeier et al. 2001;
Richards et al. 2002). Thus it is not surprising
that formestane signiﬁcantly reduced THF-diol
stimulation of MCF-7 cell proliferation at con-
centrations that block AROM activity (Sonne-
Hansen and Lykkesfeldt 2005). AROM could
be a site of THF-diol regulation in MCF-7
cells. Whether this is because of direct effects of
the THF-diols on this enzyme or via the induc-
tion of COX enzymes and PGE2 as suggested
above remains to be resolved.
As a final component of this study, we
assessed THF-diol effects on the expression
(RNA and protein) of PLA2, COX-1, COX-2,
LOX-5, LOX-12, and AROM genes in MCF-7
cells by real-time PCR and their proteins
(PLA2, COX-1, COX-2, LOX-5, LOX-12,
AROM) by Western blot analyses. The QPCR
studies (Figure 1) show that the THF-diols sig-
nificantly stimulated the expression of the
PLA2, LOX-5, LOX-12, and COX-2 genes in
MCF-7 cells and this was conﬁrmed at the pro-
tein level by Western analyses as well (Figure 2).
The protein expression pattern of PLA2,
COX-1, COX-2, LOX-5, LOX-12, and
AROM in response to THF-diols (Figure 2)
precisely mirrored the RNA expression data
(Figure 1). Thus, there are multiple genomic
sites of regulation in this lipogenic pathway,
and it is likely that these genes are coordinately
regulated by THF-diols. The induction of these
genes would result in increased intracellular
concentrations of arachidonic and linoleic
acids, prostaglandins, HETEs, and HODEs
that are directly involved in the regulation of
cell proliferation (Jiang et al. 2006; Kim et al.
2005; Nie et al. 2006; Thomas et al. 2006).
Although 24 hr of treatment is a long exposure
period to observe THF-diol effects on the
expression of these genes, metabolism is a likely
component of THF-diol action (Markaverich
BM, unpublished observation). THF-diols are
not recovered in animal tissues after the admin-
istration of doses that block reproductive func-
tion (Markaverich et al. 2007), and we have
been unable to recover [14C]THF-diols from
MCF-7 cells even though the compounds are
readily recovered in the culture medium
(Markaverich BM, unpublished observations).
Thus, we expect that a metabolite(s) represents
the intracellular regulatory component of the
THF-diols. Studies are currently under way to
define the temporal relationships between
THF-diol stimulation of the expression
(mRNA and protein) of PLA2, COX-2, LOX-5
and LOX-12, and MCF-7 cell proliferation
in vitro and in vivo.
The observations that THF-diols regulate
the activities and/or expression of PLA2,
COX-2, LOX-5, and LOX-12 are very exciting.
Fatty acids and various metabolites directly
stimulate PLA2, LOX ,and COX gene expres-
sion through a multiplicity of mechanisms
(Badawi et al. 1998; Dolan-O’Keefe et al.
2000; Jump 2004). We suspect that THF-diols
act through similar mechanisms to directly
stimulate PLA2, COX-2, LOX-5, and LOX-12
gene expression. Because the effects of formes-
tane on THF-diol stimulation of MCF-7 cell
proliferation were very minimal (Table 1), this
could have occurred indirectly through effects
on COX pathways (Brueggemeier et al. 2001)
as opposed to direct effects on AROM. Studies
are currently under way to address these issues
and identify the active metabolites of the
THF-diols in breast cancer cells.
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